 Mitotane
"Mitotane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
| Descriptor ID |
D008939
|
| MeSH Number(s) |
D02.455.526.439.681
|
| Concept/Terms |
Mitotane- Mitotane
- o,p-DDD
- Mytotan
- ortho,para-DDD
- ortho,para DDD
|
Below are MeSH descriptors whose meaning is more general than "Mitotane".
Below are MeSH descriptors whose meaning is more specific than "Mitotane".
This graph shows the total number of publications written about "Mitotane" by people in this website by year, and whether "Mitotane" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 1 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 3 | 0 | 3 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitotane" by people in Profiles.
-
Schiavon A, Saba L, Evaristo C, Petiti J, Pignochino Y, Ferrero G, Giordano G, Tucciarello C, Puglisi S, Reimondo G, Terzolo M, Lo Iacono M. Mitotane activates ATF4/ATF3 axis triggering endoplasmic reticulum stress in adrenocortical carcinoma cells. Biomed Pharmacother. 2025 Mar; 184:117917.
-
Del Rivero J, Else T, Hallanger-Johnson J, Kiseljak-Vassiliades K, Raj N, Reidy-Lagunes D, Srinivas S, Gilbert J, Vaidya A, Aboujaoude E, Bancos I, Tito Fojo A. A review of mitotane in the management of adrenocortical cancer. Oncologist. 2024 Sep 06; 29(9):747-760.
-
Wierman ME. Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? Lancet Oncol. 2024 May; 25(5):534-535.
-
Wierman ME, Vassiliades KK. ADRENOCORTICAL CARCINOMA: AN ORPHAN MALIGNANCY: FROM THE PATIENT TO THE BENCH AND BACK. Trans Am Clin Climatol Assoc. 2024; 134:113-122.
-
Schiavon A, Saba L, Catucci G, Petiti J, Puglisi S, Borin C, Reimondo G, Gilardi G, Giachino C, Terzolo M, Lo Iacono M. Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management. Int J Mol Sci. 2023 Nov 24; 24(23).
-
Kiseljak-Vassiliades K, Bancos I, Hamrahian A, Habra M, Vaidya A, Levine AC, Else T. American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. Endocr Pract. 2020 Nov; 26(11):1366-1383.
-
Germano A, Rossin D, Leoni V, Iaia N, Saba L, Basile V, Puglisi S, Caccia C, Poli G, Biasi F, Terzolo M. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. Cells. 2020 04 04; 9(4).
-
Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, Berchialla P, Porpiglia F, Veltri A, Volante M, Reimondo G, Berruti A, Terzolo M. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur J Endocrinol. 2019 Jun 01; 180(6):387-396.
-
Germano A, Saba L, De Francia S, Rapa I, Perotti P, Berruti A, Volante M, Terzolo M. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. PLoS One. 2018; 13(5):e0196931.
-
Reimondo G, Puglisi S, Zaggia B, Basile V, Saba L, Perotti P, De Francia S, Volante M, Zatelli MC, Cannav? S, Terzolo M. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. Eur J Endocrinol. 2017 Oct; 177(4):361-367.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|